Australian medicinal cannabis producer Little Green Pharma (LGP) has been granted a product registration for its 16% THC “Billinol LGP” cannabis flower medicine by the Danish Medicines Agency.
The Billinol LGP, which will be cultivated and produced at Little Green Pharma’s Denmark facility, will be the first locally produced cannabis medicine granted registration in Denmark, with LGP only the second supplier to have a registered flower medicine in country.
LGP, which expects to distribute its first products to patients before the end of the calendar year, said the registration was aligned with the Group’s strategy of being first to market in key territories, including Australia, France and Poland.
LGP has successfully employed this strategy previously in Australia and France and expects to repeat it in Poland and now Denmark in the future,” the company said in a statement.
“The registration also gives the Group significant access to the 27 million people living in the Nordic region.
“Under mutual recognition agreements with Sweden, Norway and Finland, as well as through direct prescription by Danish prescribers, patients prescribed medicinal cannabis from these countries can access registered Danish cannabis medicines supplied by Danish distributors.”
